Stifel downgraded BioMarin (BMRN) to Hold from Buy with a price target of $61, down from $73.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BMRN:
- BioMarin price target lowered to $88 from $95 at Bernstein
- BioMarin: FDA accepts for Priority Review sBLA for Palynziq
- Biomarin’s Acquisition Strategy: Navigating Risks and Challenges for Future Growth
- BioMarin’s Earnings Call: Growth Amid Challenges
- BioMarin price target lowered to $80 from $90 at Truist